Barclays lowered the firm’s price target on BioMarin (BMRN) to $80 from $86 and keeps an Overweight rating on the shares. The company reported a “modest miss” to Q3 estimates and its 2025 Voxzogo guidance was reiterated, the analyst tells investors in a research note. The firm believes BioMarin’s pipeline progress is largely on track.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Reports Strong Q3 2025 Revenue Growth
- BioMarin Pharmaceutical: Strategic Adjustments and Future Potential Justify Buy Rating Despite Revenue Miss
- BioMarin’s BMN 349 Study: A New Hope for Alpha 1-Antitrypsin Deficiency
- BioMarin lowers 2025 non-GAAP EPS view to $3.50-$3.60 from $4.40-$4.55
- BioMarin reports Q3 adjusted EPS 12c, consensus 7.6c